GLP-1 & weight-loss clinical trials in Connecticut
6 GLP-1 or weight-loss trials are recruiting in Connecticut as of July 14, 2026, with sites in Hamden, New Haven, Stamford, Waterbury. Many studies reimburse time and travel — the amount is set by each study and confirmed when you contact the team.
- A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Phase 2 · ~1481 participants · NCT06143956
Studied intervention: Tirzepatide
Connecticut site: Stamford
- A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Osteoarthritis (OA) of the Knee
Phase 3 · ~800 participants · NCT07153471
Studied intervention: Orforglipron
Connecticut site: Waterbury
- A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
Phase 3 · ~125 participants · NCT06672549
Studied intervention: Orforglipron
Connecticut sites: New Haven, Stamford
- Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
Phase 3 · ~1200 participants · NCT07284979
Studied intervention: Semaglutide
Connecticut sites: Hamden, Stamford
- A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities
Phase 3 · ~150 participants · NCT06672939
Studied intervention: Orforglipron
Connecticut site: Stamford
- Obesity Complicating Type 1 Diabetes: GLP-1 Analogue Anti-obesity Treatment
Phase 2 · ~54 participants · NCT06411210
Studied intervention: Semaglutide Pen Injector
Connecticut site: New Haven
What joining a GLP-1 trial in Connecticut actually involves
Every study above is registered on ClinicalTrials.gov, the US National Library of Medicine's public registry, and each link goes straight to that record — the one place the eligibility criteria, the schedule of visits and the contact details are kept current. A recruiting listing means the study is actively enrolling; it does not mean you are eligible until the study team screens you.
- Reimbursement is not the same as payment. Many studies cover time and travel, but the amount is set per study and confirmed by the team — treat any specific figure you see elsewhere as unverified until they tell you.
- You may receive a placebo. Most of these are randomized, so joining is not a guaranteed route to the active drug. That is worth weighing if your goal is treatment rather than contributing to the evidence.
- Trial participation is free to join and separate from a prescription. If your aim is to start a GLP-1 now, compare the cash-pay routes instead — trials are a different path with a different purpose.
Source: ClinicalTrials.gov (US National Library of Medicine), public-domain data, snapshot July 14, 2026. This is not medical advice or a recruitment service — confirm status, eligibility, and compensation on each linked ClinicalTrials.gov record and discuss any trial with your clinician.